Floatz logo

gi-4000

Psychotic Disorders

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'svaccineDormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Psychotic Disorders cohort.

Asset / SponsorPhaseRating
Risperdal
Northwell Health
Phase 4BBB
Olanzapine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BBB
CITALOPRAM
Northwell Health
Phase 4BBB
Cipralex
Northwell Health
Phase 4BBB

View all 50 →

Same molecule, other indications

gi-4000 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →